Fairmount Funds Management LLC - 11 May 2026 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: VRDN
Reported as of: 11 May 2026
Net transaction value: +$19,999,990
SEC form: 4
Accepted by SEC: 13 May 2026, 16:31:15 UTC
Prior SEC filing: 01 Apr 2026
Next SEC filing: 29 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Peter Harwin, Managing Member of Fairmount Funds Management LLC

Key filing fact

Fairmount Funds Management LLC filed Form 4 for Viridian Therapeutics, Inc.\DE (VRDN) on 13 May 2026.

Key facts

This page summarizes Fairmount Funds Management LLC's Form 4 filing for Viridian Therapeutics, Inc.\DE (VRDN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 May 2026, 16:31.

Change

Previous filing in this sequence was filed on 01 Apr 2026.
Current net transaction value: +$19,999,990.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (3)

CIK 0001802528 Primary reporting owner

Fairmount Funds Management LLC

Relationship: Director, 10%+ Owner
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Peter Harwin, Managing Member of Fairmount Funds Management LLC
Signature date: 13 May 2026

CIK 0001830382

Fairmount Healthcare Fund II GP LLC

Relationship: Director, 10%+ Owner
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Peter Harwin, Managing Member of Fairmount Healthcare Fund II GP LLC
Signature date: 13 May 2026

CIK 0001769651

Fairmount Healthcare Fund II L.P.

Relationship: Director, 10%+ Owner
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Peter Harwin, Managing Member of Fairmount Healthcare Fund II L.P.
Signature date: 13 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VRDN transaction

Common Stock

Purchase

Transaction value: $19,999,990
Shares: +1,176,470
Change %: +30%
Price: $17.00
Shares after: 5,090,928
Date: 11 May 2026
Ownership: By Fairmount Healthcare Fund II L.P.
Footnotes: F1

VRDN transaction

Common Stock

Purchase

Transaction value: $19,999,990
Shares: +1,176,470
Change %: +30%
Price: $17.00
Shares after: 5,090,928
Date: 11 May 2026
Ownership: By Fairmount Healthcare Fund II L.P.
Footnotes: F1

VRDN transaction

Common Stock

Purchase

Transaction value: $19,999,990
Shares: +1,176,470
Change %: +30%
Price: $17.00
Shares after: 5,090,928
Date: 11 May 2026
Ownership: By Fairmount Healthcare Fund II L.P.
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Fairmount Funds Management LLC ("Fairmount") and Fairmount Healthcare Fund II GP LLC ("Fairmount GP II") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

SEC remarks

The Reporting Persons may each be deemed a director by deputization of Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of Issuer and is also a Managing Member of Fairmount Funds Management LLC.